Stock 0QCV ABBVIE INC.
Add to a list
To use this feature you must be a member
Log inSign up

News AbbVie Inc. London S.E.

Equities

0QCV

US00287Y1091

Market Closed - London S.E.
Other stock markets
 11:30:00 2024-04-25 am EDT 		5-day change 1st Jan Change
166.8 USD -1.27% Intraday chart for AbbVie Inc. +1.15% +7.87%
Apr. 25 Cigna to offer Humira rivals with $0 copay at specialty pharmacy RE
Apr. 25 AbbVie Says Rinvoq Shows Superiority Versus Dupixent in Atopic Dermatitis Trial Primary Endpoint MT

Summary

Search
See the results
Unlock all the news on all businesses: Never miss an investment opportunity again!
100% Free Registration
Cigna to offer Humira rivals with $0 copay at specialty pharmacy
RE
AbbVie Says Rinvoq Shows Superiority Versus Dupixent in Atopic Dermatitis Trial Primary Endpoint
MT
New Data Show RINVOQ® (upadacitinib) Demonstrated Superiority Versus DUPIXENT® (dupilumab) Across Primary and All Secondary Endpoints in an Open-Label Head-to-Head Atopic Dermatitis Study
PR
Scholz promises support for pharma sector in Germany as Merck invests
RE
Allergan Aesthetics Invites Consumers to Be the Face of BOTOX Cosmetic and Their Other Biggest Brands
AQ
US CDC warns of harmful reactions to fake Botox injections
RE
Allergan Aesthetics Invites Consumers to Be the Face of BOTOX® Cosmetic (onabotulinumtoxinA) and Their Other Biggest Brands
PR
Pfizer: new Emblaveo antibiotic approved in the EU
CF
Sector Update: Health Care Stocks Advance Late Afternoon
MT
Sector Update: Health Care Stocks Rise Friday Afternoon
MT
Sector Update: Health Care
MT
Alvotech Shares Rise After Signing Agreement to Expand Access to Humira Biosimilar Adalimumab-ryvk in US
MT
AbbVie - Phase 3 SELECT-GCA Study of Upadacitinib showed Positive Results in Patients with Giant Cell Arteritis
AQ
Deutsche Bank Raises AbbVie's Price Target to $175 Form $170
MT
Alvotech Signs Agreement to Expand Access to Humira Biosimilar Adalimumab-ryvk in US
MT
Global markets live: DocMorris, Microsoft, Oracle, Micron, Netflix...
Our Logo
AbbVie Says Potential Treatment for Giant Cell Arteritis Met Endpoints in Phase 3 Study
MT
AbbVie Study on Treatment for Giant Cell Arteritis Meets Primary Endpoint
DJ
Phase 3 SELECT-GCA Study of Upadacitinib (RINVOQ®) Showed Positive Results in Patients With Giant Cell Arteritis
PR
AbbVie Announces Positive Top-Line Results from SELECT-GCA Study of Upadacitinib Showed Positive Results in Patients with Giant Cell Arteritis
CI
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. ABBV Stock
  4. 0QCV Stock
  5. News AbbVie Inc.